AtaiBeckley Inc.
ataibeckley.comWhat Do They Do?
Develops investigational psychedelic-based treatments for patients with difficult-to-treat mental health conditions, including depression and anxiety.
10-K for FY2025, filed Mar 6, 2026Founded in 2025 through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited, AtaiBeckley is a clinical-stage…View ↗
We have built a diversified pipeline of investigational psychedelic-based neuroplastogens designed to address some of the most urgent unmet…View ↗
BPL-003: Nasal spray mebufotenin (5-MeO-DMT) benzoate for treatment-resistant depression (“TRD”);View ↗
VLS-01: Buccal film dimethyltryptamine (“DMT”) for TRD;View ↗
EMP-01: Oral formulation of a stable HCl salt form of the R-enantiomer of 3,4-methylenedioxy-methamphetamine (“R-MDMA”) for social anxiety…View ↗
How Do They Make Money?
Most revenue comes from Nualtis customers paying for research and development services using its oral thin-film drug-delivery technology; some payments arrive upfront and are earned as Nualtis performs the work. The company also receives payments for technology licenses, including upfront and manufacturing-milestone payments.
10-K for FY2025, filed Mar 6, 2026Nualtis recognizes revenue from various research and development agreements. In these agreements, Nualtis is responsible for performing…View ↗
In addition to the Company's license revenue, the Company recognizes revenue through various research and development agreements through…View ↗
For the years ended December 31, 2025 and 2024, the Company had contract liabilities of $1.5 million and $0.7 million, respectively, which…View ↗
In January 2025, the Company, through its wholly owned subsidiary Nualtis, entered into an Amended & Restated Asset Purchase Agreement…View ↗
$4.1M
-
10-K for FY2025, filed Mar 6, 2026
$4.1M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
License Revenue
Licensed
|
4.9% |
License Revenue, FY2025
$202K Sources
|
Licensed |
|
Research and Development Services Revenue
Recurring
10-K for FY2025, filed Mar 6, 2026 |
95% |
Research and Development Services Revenue, FY2025
$3.9M Sources
|
Recurring |
Who Are Their Customers?
Drug developers engage Nualtis for research and development using its oral thin-film drug-delivery technology; some agreements also give Nualtis a possible manufacturing role after approval.
10-K for FY2025, filed Mar 6, 2026
Do Revenues Turn Into Profits?
No. It lost $660M in FY2025.
10-K for FY2025, filed Mar 6, 2026
−$644.1MView ↗
10-K for FY2025, filed Mar 6, 2026
−$660MView ↗
10-K for FY2025, filed Mar 6, 2026
−$103.6MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$32.5MView ↗
- ▲ +17% (Loss)
- vs −$27.7M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 11, 2026
Open tableView ↗
-
Aug 31, 2026
Regulatory review advances for Lilly merger
The U.S. antitrust waiting period expired; U.K. authorities had no further questions, while Australian clearance remained subject to a waiting period.
Sources
8-K, filed Aug 31, 2026
The applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with the Merger…View ↗
-
Jul 16, 2026
Lilly agrees to acquire AtaiBeckley
Shareholders would receive $6.75 per share in cash at closing, plus up to $2.50 per share in contingent payments tied to clinical and regulatory milestones.
Sources
8-K, filed Jul 16, 2026
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, at the effective time of the Merger (the…View ↗
Who Do They Compete With?
Competes with Usona Institute, Multidisciplinary Association for Psychedelic Studies, GH Research, Helus Pharma, Definium Therapeutics, Neumora Therapeutics, Alto Neuroscience, Xenon Pharmaceuticals, AbbVie, Acadia Pharmaceuticals, COMPASS, VistaGen Therapeutics, and Engrail Therapeutics
10-K for FY2025, filed Mar 6, 2026The commercial opportunity for our product candidates could reduce or be eliminated if our competitors develop and commercialize products…View ↗
Loading...
